Agency Information Collection Activities: Proposed Collection: Comment Request, 66787-66788 [E6-19377]

Download as PDF Federal Register / Vol. 71, No. 221 / Thursday, November 16, 2006 / Notices to the Administration for Children and Families, Office of Administration, Office of Information Services, 370 L’Enfant Promenade, SW., Washington, DC 20447, Attn: ACF Reports Clearance Officer. E-mail address: infocollection@acf.hhs.gov. All requests should be identified by the title of the information collection. The Department specifically requests comments on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency’s estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication. Dated: November 9, 2006. Robert Sargis, Report Clearance Officer. [FR Doc. 06–9223 Filed 11–15–06; 8:45 am] BILLING CODE 4184–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES Administration for Children and Families Proposed Information Collection Activity; Comment Request Title: Public Education Study on Public Knowledge of Abstinence and Abstinence Education. OMB No.: New Collection. Description: In support of the goal to prevent unwed childbearing, pregnancy, and sexually transmitted diseases, Congress has recently authorized funding increases to support abstinence education. 66787 To learn more about the public’s views, the Administration for Children and Families (ACF) will conduct a public opinion survey of a nationally representative sample of adolescents (age 12 to 18) and their parents to examine current attitudes on abstinence and knowledge of abstinence education. The survey data will be used to inform current and future public education campaigns. In addition, the information gathered will assist ACF with grant administration and technical assistance activities. The survey will ask parents (one parent per adolescent) and adolescents about their views and attitudes about abstinence until marriage, awareness of abstinence education, and views and attitudes about abstinence education. Each parent and adolescent interview will take approximately 20 minutes to complete. Respondents: A nationally representative sample of adolescents will be selected through a random-digitdial sample of households with landline telephones. ANNUAL BURDEN ESTIMATES Instrument Number of respondents Number of responses per respondent Average burden hours per response Total burden hours Telephone interview ......................................................................................... 1 2,000 1 0.33 660 pwalker on PROD1PC61 with NOTICES 1 1,000 adolescent/parent pairs. Total annual burden estimates: 660. In compliance with the requirements of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Administration for Children and Families is soliciting public comment on the specific aspects of the information collection described above. Copies of the proposed collection of information can be obtained and comments may be forwarded by writing to the Administration for Children and Families, Office of Administration, Office of Information Services, 370 L’Enfant Promenade, SW., Washington, DC 20447, Attn: ACF Reports Clearance Officer. E-mail address: infocollection@acf.hhs.gov. All requests should be identified by the title of the information collection. The Department specifically requests comments on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency’s estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) VerDate Aug<31>2005 20:27 Nov 15, 2006 Jkt 211001 ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication. Dated: November 8, 2006. Robert Sargis, Reports Clearance Officer. [FR Doc. 06–9224 Filed 11–15–06; 8:45 am] BILLING CODE 4184–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES Health Resources and Services Administration Agency Information Collection Activities: Proposed Collection: Comment Request In compliance with the requirement for opportunity for public comment on proposed data collection projects (section 3506(c)(2)(A) of Title 44, United States Code, as amended by the Paperwork Reduction Act of 1995, Pub. PO 00000 Frm 00039 Fmt 4703 Sfmt 4703 L. 104–13), the Health Resources and Services Administration (HRSA) publishes periodic summaries of proposed projects being developed for submission to the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995. To request more information on the proposed project or to obtain a copy of the data collection plans and draft instruments, call the HRSA Reports Clearance Officer on (301) 443–1129. Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency’s estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. E:\FR\FM\16NON1.SGM 16NON1 66788 Federal Register / Vol. 71, No. 221 / Thursday, November 16, 2006 / Notices Proposed Project: Health Resources and Services Administration Core Clinical Measures Implementation Feasibility Study In response to the Health and Human Service’s Department-wide objectives and HRSA’s strategic goals, a set of core clinical performance measures have been established. These measures will assist in the evaluation of HRSA program performance in defined clinical areas to facilitate quality improvement activities for HRSA and its grantees. The purpose of the proposed voluntary feasibility study is to learn from HRSA’s health service delivery grantees, which have different reporting capacities, about their abilities to report national standardized measures. More specifically, the study will help HRSA to understand: (1) The factors involved in the HRSA grantee decision making processes around measure selection/ choice; (2) Grantees’ data collection capacity including tools, processes and infrastructure; (3) Level of grantee effort involved in measure reporting; and (4) How the performance process will impact the grantees’ quality improvement efforts. Overall the feasibility study will allow HRSA to query its grantees related to the newly Responses per respondent Number of respondents introduced core clinical performance measure set. The feasibility study includes the actual data collection of the proposed clinical measures along with a report form to assess burden, data collection and reporting capacity, and technical assistance needs. Additionally, the study will provide HRSA with the opportunity to refine instructions and performance measure definitions accordingly in preparation for the actual implementation of the clinical measures. The estimated annualized response burden is as follows: Total responses Hours per response Total hour burden Clinical Measures ............................................................... Report Form ....................................................................... 50 50 1 1 50 50 40 1.5 2,000 75 Total ............................................................................ 50 ........................ 50 .......................... 2075 Send comments to Susan G. Queen, Ph.D., HRSA Reports Clearance Officer, Room 10–33, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857. Written comments should be received within 60 days of this notice. Dated: November 8, 2006. Cheryl R. Dammons, Director, Division of Policy Review and Coordination. [FR Doc. E6–19377 Filed 11–15–06; 8:45 am] BILLING CODE 4165–15–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing National Institutes of Health, Public Health Service, HHS. ACTION: Notice. pwalker on PROD1PC61 with NOTICES AGENCY: SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the VerDate Aug<31>2005 20:27 Nov 15, 2006 Jkt 211001 Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/ 496–7057; fax: 301/402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. Second Generation Nitric OxideReleasing Non-Steroidal AntiInflammatory Drugs Possessing a Diazeniumdiolate Group (NONO– NSAIDs) Description of Technology: Nonsteroidal anti-inflammatory drugs (NSAIDs) are one of the most useful clinical therapies for the treatment of pain, fever and inflammation. It is estimated that more than 30 million people take NSAIDs every day. However, the major mechanism by which NSAIDs exert their antiinflammatory activity is also responsible for the gastrointestinal, renal and hepatic side effects observed in patients undergoing long-term treatment of chronic conditions. The most common side effects associated with NSAID administration are gastroduodenal erosions and ulcerations affecting around 15% of chronic NSAID users. While many of these clinical manifestations are mild, they may develop into serious events such as bleeding, perforation, obstruction, and sudden death. Therefore, the gastric irritant effect of NSAIDs (particularly aspirin) can be a deterrent to its longterm use for the prophylactic prevention of adverse cardiovascular events such as stroke and myocardial infarction, or as PO 00000 Frm 00040 Fmt 4703 Sfmt 4703 a safe chemopreventive agent to avoid the recurrence of colorectal cancer (CRC). One of the main strategies that have emerged to improve the safety profile of NSAIDs is the linkage of a nitric oxide (NO)-releasing moiety to the structure of classical NSAIDs (NO–NSAIDs). However, all NO-releasing NSAIDs published so far have a nitrooxyalkyl group as the NO-releasing group. An important drawback to this design is the fact that production of NO (only one equivalent) from organic nitrate esters requires a metabolic three-electron reduction in vivo, and this activation decreases in efficiency on continued use of the drugs, contributing to ‘‘nitrate tolerance’’. This invention describes the design, synthesis and biological evaluation of novel NO-releasing non-steroidal antiinflammatory prodrugs (NONO– NSAIDs) possessing a N-diazen-1-ium1,2-diolate (NONOate), which offers additional advantages compared with organic nitrate-based NO–NSAIDs: (a) Simultaneous release of the corresponding NSAID and NO. (b) Production of two equivalents of NO (twice as much) by a first-order rate. (c) Metabolic activation (hydrolysis) mediated by non-specific esterases, which unlike redox metabolism, is not expected to produce tolerance upon long-term treatment. Applications: This invention provides a group of anti-inflammatory, analgesic, and gastrointestinal safe prodrugs, which are expected to be a suitable alternative for the prophylactic prevention of adverse cardiovascular E:\FR\FM\16NON1.SGM 16NON1

Agencies

[Federal Register Volume 71, Number 221 (Thursday, November 16, 2006)]
[Notices]
[Pages 66787-66788]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-19377]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration


Agency Information Collection Activities: Proposed Collection: 
Comment Request

    In compliance with the requirement for opportunity for public 
comment on proposed data collection projects (section 3506(c)(2)(A) of 
Title 44, United States Code, as amended by the Paperwork Reduction Act 
of 1995, Pub. L. 104-13), the Health Resources and Services 
Administration (HRSA) publishes periodic summaries of proposed projects 
being developed for submission to the Office of Management and Budget 
(OMB) under the Paperwork Reduction Act of 1995. To request more 
information on the proposed project or to obtain a copy of the data 
collection plans and draft instruments, call the HRSA Reports Clearance 
Officer on (301) 443-1129.
    Comments are invited on: (a) Whether the proposed collection of 
information is necessary for the proper performance of the functions of 
the agency, including whether the information shall have practical 
utility; (b) the accuracy of the agency's estimate of the burden of the 
proposed collection of information; (c) ways to enhance the quality, 
utility, and clarity of the information to be collected; and (d) ways 
to minimize the burden of the collection of information on respondents, 
including through the use of automated collection techniques or other 
forms of information technology.

[[Page 66788]]

Proposed Project: Health Resources and Services Administration Core 
Clinical Measures Implementation Feasibility Study

    In response to the Health and Human Service's Department-wide 
objectives and HRSA's strategic goals, a set of core clinical 
performance measures have been established. These measures will assist 
in the evaluation of HRSA program performance in defined clinical areas 
to facilitate quality improvement activities for HRSA and its grantees. 
The purpose of the proposed voluntary feasibility study is to learn 
from HRSA's health service delivery grantees, which have different 
reporting capacities, about their abilities to report national 
standardized measures. More specifically, the study will help HRSA to 
understand: (1) The factors involved in the HRSA grantee decision 
making processes around measure selection/choice; (2) Grantees' data 
collection capacity including tools, processes and infrastructure; (3) 
Level of grantee effort involved in measure reporting; and (4) How the 
performance process will impact the grantees' quality improvement 
efforts. Overall the feasibility study will allow HRSA to query its 
grantees related to the newly introduced core clinical performance 
measure set.
    The feasibility study includes the actual data collection of the 
proposed clinical measures along with a report form to assess burden, 
data collection and reporting capacity, and technical assistance needs. 
Additionally, the study will provide HRSA with the opportunity to 
refine instructions and performance measure definitions accordingly in 
preparation for the actual implementation of the clinical measures.
    The estimated annualized response burden is as follows:

----------------------------------------------------------------------------------------------------------------
                                    Number of    Responses  per       Total         Hours per       Total hour
                                   respondents      respondent      responses        response         burden
----------------------------------------------------------------------------------------------------------------
Clinical Measures..............              50               1              50             40             2,000
Report Form....................              50               1              50              1.5              75
                                --------------------------------------------------------------------------------
    Total......................              50  ..............              50  ...............            2075
----------------------------------------------------------------------------------------------------------------

    Send comments to Susan G. Queen, Ph.D., HRSA Reports Clearance 
Officer, Room 10-33, Parklawn Building, 5600 Fishers Lane, Rockville, 
MD 20857. Written comments should be received within 60 days of this 
notice.

    Dated: November 8, 2006.
Cheryl R. Dammons,
Director, Division of Policy Review and Coordination.
[FR Doc. E6-19377 Filed 11-15-06; 8:45 am]
BILLING CODE 4165-15-P